The Competitive
Intelligence Lag

In 2022, a mid-stage oncology biotech made a pivotal portfolio decision based on a competitive landscape analysis. The analysis was thorough — forty pages, sourced from Evaluate Pharma and SEC filings, reviewed by an external consultant. It was also, in the ways that mattered most, six months out of date. A competitor's Phase 2 data, presented at ESMO that September, had fundamentally changed the efficacy bar for the indication. The biotech didn't know. They'd closed the analysis in March.

Clinical development moves faster than most internal intelligence cycles. Between a congress presentation, an IND amendment, a press release, a ClinicalTrials.gov update, and a published manuscript — the competitive landscape for any given indication can materially shift multiple times in a single quarter.

Most emerging biotech companies run competitive intelligence processes that capture a snapshot every six to twelve months. They assign the task to someone who has twelve other things on their plate, source from the same public databases, and present the findings to leadership once. By the time the information reaches a decision, it's already aged.

The companies that get this right don't have more access to information than anyone else. They have shorter cycle times between the signal appearing and a decision-maker seeing it in context. That compression comes from infrastructure, not effort.

The intelligence that matters in clinical development is rarely a single data point. It's the pattern — the competitor who expanded inclusion criteria in their latest protocol amendment, the biomarker hypothesis that showed up in two different Phase 1 reports from different sponsors, the FDA advisory committee comment that changes what an acceptable endpoint looks like. Seeing any one of these in isolation means little. Seeing all three connected to your program's design decisions is the difference between catching the signal and missing it.